STEMCO Biomedical announced today that its intellectual property position has been enhanced by issuance of US patent 6627759. This patent protects STEMCO Biomedical's core technology - a flow cytometric aldehyde dehydrogenase [ALDH] assay using a proprietary substrate and multidrug resistance inhibitors to detect ALDH activity in stem cells. STEMCO Biomedical recently launched ALDEFLUORtm, the first in a series of products designed to identify, enumerate, and isolate stem cells for research and clinical applications. The patent was issued to Duke University and has been exclusively licensed to STEMCO Biomedical.
STEMCO Biomedical has filed a 510(k) clearance to market its second product ALDECOUNT™ with the FDA. ALDECOUNT is an in-vitro diagnostic device which will enumerate Hematopoietic progenitor cells in bone marrow transplants based on the cellular levels of Aldehyde dehydrogenase (ALDH).
About STEMCO Biomedical
StemCo Biomedical, Inc. was founded in 1999 and is located in the Research Triangle Park area of NC. The Company is engaged in the development, manufacture and distribution of a series of medical products designed to improve therapeutic transplantation of adult hematopoietic stem and progenitor cells derived from bone marrow, peripheral blood, or umbilical cord blood. Addressing a market of more than $1 billion annually, the Company will have a series of products on the market starting in 2002 that identify, sort and custom-engineer stem cell grafts based upon cellular expression of ALDH resulting in what may be better, more effective stem cell transplants in the future.
For further information please contact:
Noel R Brown
Director of Marketing
STEMCO Biomedical, Inc.
2810 Meridian Parkway, Suite 148
Durham NC 27713 USA
Tel 919 484 2571 x 224
Fax 919 484 8792
© the trelys funds